CR20230282A - Derivados de indol útiles en el tratamiento de afecciones asociadas con cgas - Google Patents

Derivados de indol útiles en el tratamiento de afecciones asociadas con cgas

Info

Publication number
CR20230282A
CR20230282A CR20230282A CR20230282A CR20230282A CR 20230282 A CR20230282 A CR 20230282A CR 20230282 A CR20230282 A CR 20230282A CR 20230282 A CR20230282 A CR 20230282A CR 20230282 A CR20230282 A CR 20230282A
Authority
CR
Costa Rica
Prior art keywords
cgas
conditions associated
treating conditions
indole derivatives
derivatives useful
Prior art date
Application number
CR20230282A
Other languages
English (en)
Inventor
Danilo Guerini
Richard Heng
Martin Gunzenhauser
Francesca Perruccio
Carsten Spanka
David Carcache
Florian Gruber
Oliver Simic
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20230282A publication Critical patent/CR20230282A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

La presente revelación se refiere a un compuesto de Formula (I): o a una sal, hidrato, solvato, estereoisómero o tautómero del mismo farmacéuticamente aceptable, donde R<sub>1</sub> hasta R<sub>8</sub> son como se los define en este documento, así como también a los métodos para hacerlos y usarlos.
CR20230282A 2020-12-22 2021-12-20 Derivados de indol útiles en el tratamiento de afecciones asociadas con cgas CR20230282A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063128949P 2020-12-22 2020-12-22
PCT/IB2021/062029 WO2022137085A1 (en) 2020-12-22 2021-12-20 Indole derivatives useful in treating conditions associated with cgas

Publications (1)

Publication Number Publication Date
CR20230282A true CR20230282A (es) 2023-07-12

Family

ID=79164465

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230282A CR20230282A (es) 2020-12-22 2021-12-20 Derivados de indol útiles en el tratamiento de afecciones asociadas con cgas

Country Status (19)

Country Link
US (1) US20230085472A1 (es)
EP (1) EP4267564A1 (es)
JP (1) JP2024502258A (es)
KR (1) KR20230124665A (es)
CN (1) CN116635382A (es)
AR (1) AR124443A1 (es)
AU (1) AU2021404953A1 (es)
CA (1) CA3202212A1 (es)
CL (1) CL2023001859A1 (es)
CO (1) CO2023007954A2 (es)
CR (1) CR20230282A (es)
DO (1) DOP2023000129A (es)
EC (1) ECSP23045506A (es)
IL (1) IL303913A (es)
MX (1) MX2023007467A (es)
PE (1) PE20240229A1 (es)
TW (1) TW202241873A (es)
UY (1) UY39579A (es)
WO (1) WO2022137085A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230391786A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company cGAS INHIBITORS
WO2024083773A1 (en) 2022-10-18 2024-04-25 Glaxosmithkline Intellectual Property Development Limited Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065860A1 (es) * 2007-03-29 2009-07-08 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
SG11201704770YA (en) 2014-12-22 2017-07-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
BR112020016008A2 (pt) * 2018-02-05 2020-12-15 The Rockefeller University Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica

Also Published As

Publication number Publication date
WO2022137085A1 (en) 2022-06-30
DOP2023000129A (es) 2023-07-16
PE20240229A1 (es) 2024-02-16
AU2021404953A1 (en) 2023-06-22
IL303913A (en) 2023-08-01
EP4267564A1 (en) 2023-11-01
JP2024502258A (ja) 2024-01-18
UY39579A (es) 2022-07-29
CN116635382A (zh) 2023-08-22
CL2023001859A1 (es) 2024-02-09
AR124443A1 (es) 2023-03-29
CA3202212A1 (en) 2022-06-30
KR20230124665A (ko) 2023-08-25
ECSP23045506A (es) 2023-07-31
TW202241873A (zh) 2022-11-01
MX2023007467A (es) 2023-07-04
US20230085472A1 (en) 2023-03-16
AU2021404953A9 (en) 2024-02-08
CO2023007954A2 (es) 2023-06-30

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
CR20230282A (es) Derivados de indol útiles en el tratamiento de afecciones asociadas con cgas
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
NZ724229A (en) Anti-egfrviii antibodies and uses thereof
MX2021005398A (es) Terapia del cancer con celulas inmunitarias anti-cd33.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2022000726A (es) Anticuerpos inmunomoduladores y metodos de uso de los mismos.
MX2022007775A (es) Composición para usarse en terapia de microbiota.
AU2018337668A1 (en) Improved supraparticles
MX2022000310A (es) Inhibidores de proteina bcl-2.
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
MX2021015992A (es) Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
MX2021005395A (es) Terapia del cáncer con células inmunitarias anti-liv1.
PH12021551100A1 (en) Dried biological compositions and methods thereof
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
PH12020550217A1 (en) Nutrient-spore formulations and uses thereof
MX2021005157A (es) Composiciones, metodos para hacer y utilizar extracto de salvado de arroz.
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX2022010466A (es) Tratamiento conjunto contra tipos de cancer hematologico.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2023007114A (es) Películas solubles en agua, artículos de dosis unitaria solubles en agua y métodos de fabricación y uso de los mismos.
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
PH12019550033A1 (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
MX2023008327A (es) Anticuerpos inmunomoduladores de anticuerpo-farmaco.